<?xml version="1.0" encoding="UTF-8"?>
<p>Following HMPV exposure, an innate cell, B cell, and T cell immune response usually develops within days and assists rapid virus clearance [
 <xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,
 <xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. However, HMPV can cause both upper respiratory tract (URT) and lower respiratory tract (LRT) disease, in some cases exacerbated by immune function [
 <xref rid="B35-pathogens-09-00109" ref-type="bibr">35</xref>,
 <xref rid="B36-pathogens-09-00109" ref-type="bibr">36</xref>]. LRT disease can be severe, particularly when an individual is exposed to virus for the first time. Outcomes can include bronchiolitis and pneumonia and can result in death [
 <xref rid="B37-pathogens-09-00109" ref-type="bibr">37</xref>]. 
</p>
